Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • VIP Gloves (VIP) shares were up over 200 per cent this morning after the company has been considered an essential service by the Malaysian Government
  • VIP Gloves says its order book is fully committed until December 2020
  • These orders represent the production of approximately 100, 40-foot shipping containers of nitrile gloves, with each container holding up to four million gloves
  • Malaysia is the world’s largest manufacturer of disposable gloves, with more than 60 per cent of global production
  • The company’s Malaysian plant is operating 24 hour days
  • VIP Gloves is currently up 123 per cent on the market today, selling shares for 7.8¢ each

VIP Gloves (VIP) shares were up over 200 per cent this morning after the company has been considered an essential service by the Malaysian Government.

Glove production is in full swing at the manufacturing plant as it is operating 24 hours a day, seven days a week.

VIP Gloves says its order book is fully committed until December 2020. These orders represent the production of approximately 100, 40-foot shipping containers of nitrile gloves, with each container holding up to four million gloves.

Malaysia is the world’s largest manufacturer of disposable gloves, with more than 60 per cent of global production.

Two new production lines

The company’s two new production lines have been affected by the supplier re-alignment and fine-tuning problems. Since both new lines are under warranty, operations can only start after the adjustments are completed.

However, the suppliers fall under the non-essential workers and VIP Gloves will have to wait until April 28, when the restrictions are over.

VIP Gloves is currently up 123 per cent on the market today, selling shares for 7.8¢ each at 2:35 pm AEST.

VIP by the numbers
More From The Market Herald
Botanix Pharmaceuticals (ASX:BOT) - President & Executive Chairman, Vince Ippolito

" Botanix Pharmaceuticals (ASX:BOT) progresses clinical programs

Botanix Pharmaceuticals (BOT) progressed a number of clinical programs during the September quarter.
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham

" Recce Pharmaceuticals (ASX:RCE) receives ethics approval to begin R327 trial

Recce Pharmaceuticals (RCE) has received Human Research Ethics Committee (HREC) approval to begin its phase one intravenous (IV) trial of RECCE327 (R327).
Noxopharm (ASX:NOX) - CEO, Dr Graham Kelly

" Noxopharm (ASX:NOX) granted Australian and European patents

Noxopharm (NOX) has been granted Australian and European patents for its use of Veyonda to achieve safer chemotherapy.

" ACCC granted injunction to block Virtus Health’s (ASX:VRT) purchase of IVF clinics

Australia’s Federal Court has granted the ACCC an interlocutory injunction to temporarily stop Virtus Health (VRT) from acquiring a string of fertility clinics.